Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.62 |
| ▸ | NAAA | Q02083 | 1/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.57 |
| ▸ | FAAH | O00519 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.48 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23567476 | 1.00 | CASP2 (0.62) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL20121986 | 1.00 | CASP2 (0.62) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL20417361 | 1.00 | CASP2 (0.62) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL20121987 | 0.98 | CASP2 (0.59) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL4308618 | 0.92 | CASP2 (0.50) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL23518488 | 0.92 | MEN1 (0.52) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL26504642 | 0.85 | MEN1 (0.47) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL20417364 | 0.85 | CASP2 (0.58) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL24193577 | 0.84 | MEN1 (0.45) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL25475907 | 0.84 | MEN1 (0.45) | CASP2NAAAEPHX1FAAHMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10617676-B2 | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-14 | — | — | US | disclosed |
| US-10377753-B2 | Substituted 4-azaindoles and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-13 | — | — | US | disclosed |
| US-20180208595-A1 | SUBSTITUTED 4-AZAINDOLES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-07-26 | — | — | US | disclosed |
| US-20180125826-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (JP) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208595-A1 | SUBSTITUTED 4-AZAINDOLES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | CASP2 3793/4885NAAA 2247/4885EPHX1 2566/4885 |
| US-10377753-B2 | Substituted 4-azaindoles and their use as GluN2B receptor modulators | GRIN2B, GRIN2A, GRIN2C | CASP2 3793/4885NAAA 2247/4885EPHX1 2566/4885 |
| US-10617676-B2 | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GluN2B receptor modulators | GRIN2B, GRIN2A, GRIN2C | CASP2 4238/4885NAAA 2556/4885EPHX1 1581/4885 |
| US-20180125826-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | CASP2 4238/4885NAAA 2556/4885EPHX1 1581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.